Determination of HIV-1 subtypes in Hungary by synthetic peptides representing the V3 loop ofenv
- 1 December 1996
- journal article
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 2 (4) , 268-271
- https://doi.org/10.1007/bf02904822
Abstract
For the determination of HIV-1 diversity and serotyping of HIV-1 subtypes, an enzyme immunoassay was developed based on synthetic peptides representing immunodominant epitopes of the V3 loop of HIV-1 subtypes A, B, C and E, respectively. Sera from 53 asymptomatic HIV-1 infected individuals were tested for their pattern of binding reactivity to the synthetic peptides. 45/52 (85%) of the sera reacted exclusively to V3 peptide representing HIV-1 B subtypes, 4/52 (7.6%) of the sera showed cross reacticity to A/B peptides and 1/52 (1.9%) of the sera reacted with both A and C peptides. No single reactivity with subtype A or E peptides have been observed. Results together with nucleotide sequence analysis of the V3 region of clinical isolates suggest that HIV-1 infection in Hungary has been induced predominantly by strains belonging to HIV-1 subtype B.Keywords
This publication has 21 references indexed in Scilit:
- Determination of HIV-1 subtypes in Hungary by synthetic peptides representing the V3 loop ofenvPathology and Oncology Research, 1996
- Sequence Note: Spread of HIV Type 1 in Slovakia Remains Limited and Is Restricted to Subtype BAIDS Research and Human Retroviruses, 1996
- Identification of an env G subtype and heterogeneity of HIV-1 strains in the Russian Federation and BelarusAIDS, 1994
- Serotyping HIV Type 1 by Antibody Binding to the V3 Loop: Relationship to Viral GenotypeAIDS Research and Human Retroviruses, 1994
- Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genesScience, 1993
- Highly specific V3 peptide enzyme immunoassay for seretyping HIV-1 specimens from ThailandAIDS, 1993
- Long-Term High-Titer Neutralizing Activity Induced by Octameric Synthetic HIV-1 AntigenScience, 1991
- Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous seraAIDS, 1990
- Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.Proceedings of the National Academy of Sciences, 1989
- Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.Proceedings of the National Academy of Sciences, 1988